A
Abzu
Abzu uses an AI-powered technology suite to design better compounds for RNA therapeutics
About Abzu
Abzu is the best in class in silico pharma R&D company. Since its founding in 2018, Abzu’s proprietary explainable AI, the QLattice®, has been the cornerstone to their cutting-edge approach. Abzu is a preferred partner for pharma, biotech, and research institutions, transforming data into insights and accelerating R&D from target identification to clinical trials. Abzu has offices in Copenhagen and Barcelona, and has received €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to Cool Vendor™, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards. For more information, visit www.abzu.ai.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Copenhagen, Denmark
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Abzu.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
PSV
Inventure
Seed Capital
European Innovation Council
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abzu on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abzu on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.